drugset / Trial / NCT06458036
Selpercatinib Pre-RAI in Patients With RET Fusion Thyroid Cancer (RAISE)
Phase 2
Recruiting
13 enrolled
Children's Hospital of Philadelphia
Eli Lilly and Company · collabUnited States Department of Defense · collab
NaSingle-groupOpen-labelTreatment
Summary
Papillary thyroid cancer (PTC) is the most common form of differentiated thyroid cancer (DTC). The traditional first line treatment for patients with advanced DTC after surgical resection is radioactive iodine (RAI) therapy. However, less than a quarter of patients with lung metastases will achieve a complete response to RAI therapy, and this therapy carries the risk of pulmonary fibrosis and an increasingly recognized risk of secondary malignancies.
Timeline
- Start
- 2024-07-29
- Primary completion
- 2030-11-01
- Completion
- 2031-11-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Selpercatinib | Small molecule | — | — |